Advanced Diabetes Technology – Conversations and Collaborations Enduring Activity
CME Credits:
1
MOC Credits:
1

Online

Advanced Diabetes Technology – Conversations and Collaborations Enduring Activity

AACE’s Advanced Diabetes Technology – Conversations and Collaborations is designed to equip endocrine care team members with evidence-based knowledge and increased competence about how to use diabetes technology and devices to guide and modify treatment approaches for persons with diabetes. Completion of this self-paced course is encouraged prior to attending a live session as it provides foundational information that will be built upon in the live program.

1
CME Credit
1
MOC Credit

Target Audience

This educational initiative is intended for all members of the endocrine care team.

Learning Objectives

Through this education, learners will improve their abilities to:

  • Assess  differences and best uses for  continuous glucose monitors (CGMs), insulin pumps, and integrated devices.
  • Discuss appropriate settings for CGMs, connected pens, insulin pumps, and integrated devices.
  • Identify interventions which can add value to A1c interpretation and optimize “in-target” glucose values to improve patient adherence and reduce the occurrent of dysglycemia.
  • Incorporate diabetes technologies that are effective in managing patients in special populations and individual needs.
  • Navigate insurance challenges when implementing diabetes technologies.

Commercial Support

This activity is supported by independent educational grants from Abbott Diabetes Care, Dexcom, Lilly, Medtronic, and Novo Nordisk.

Faculty

Matthew J. Levine, MD, FACE
Clinical Endocrinologist
Endocrinology Fellowship Director
Scripps Clinic, La Jolla CA
Assistant Clinical Professor of Medicine, U.C. San Diego School of Medicine

Jeffrey R. Unger, MD FAAFP, FACE
Director, Unger Primary Care Concierge Medical Group

Lucy H. Thornton, MSN, APRN, FNP-BC
Division of Endocrinology
Mayo Clinic Florida

Claire Ingram, PA-C
Physician Assistant
University of Colorado Anschutz Medical Campus

Accreditation and Designation Statements

Accreditation and Designation

Physicians

The American College of Endocrinology designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses/Nurse Practitioners

This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 22085650. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Statement of Need

This initiative is designed to equip endocrine care team members with evidence-based knowledge and increased competence about how to use diabetes technology and devices to guide and modify treatment approaches for patients with diabetes.

Disclosures/Conflicts of Interest

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE)requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Faculty

Matthew Levine, MD, FACE, Novo Nordisk, speakers' bureau on diabetes; Eli Lilly, speakers' bureau on diabetes; Mannkind, consultant

Jeff Unger, MD, FAAFP, FACE, Abott Diabetes, consultant and speakers' bureau; Dexcom, consultant

Claire Ingram, PA-C, no relationships to disclose

Lucy Thornton, MSN, APRN, FNP-BC, no relationships to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.

Planners

Amy Ogunsunlade, no relationships to disclose

Diane Alberson, MEd, CAE​, no relationships to disclose

Contributer/Reviewer

Carla Cox, PhD, RDN, FADCES, Certified Diabetes Care and Education Specialist (CDCES), Certified Insulin Pump and CGM Trainer Mountain Vista Medicine, South Jordan, UT American Diabetes Association, Arlington, VA

Carla Cox, PhD, RDN, FADCES has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.